Oral Presentation Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2016

LEADER - More good news for the patients with type 2 diabetes (#154)

Timothy Davis 1
  1. University of Western Australia, Fremantle, WA, Australia

After the EmpaReg trial showed that empagliflozin was the first treatment for diabetes that reduced mortality, the LEADER trial of liraglutide in type 2 diabetes also demonstrated a significent 22% all-cause mortality benefit. Liraglutide was also associated with a significant 14% reduction in the primary edpoint (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). It proved to be a safe and well tolreated treatment apart from nausea, with no pancreatitis signal although pancreatic cancer was non-significantly increased (a result which appears different to data from DPP4 inhibitor trials). Weight loss is a futher benefit. As with empagliflozin, the FDA may require more data from other long-acting GLP1 analogues before supporting an indication for cardiovascular disease reduction, but the LEADER results are more good news for patients with type 2 diabetes.